LXRX LEXICON PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1062822 · EDGAR
- Bought, last 12 months
- $2.72M 5 purchases by 2 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 189 since 2021-08-03, latest 2026-06-04 16:14
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Artal Group S.A. | Dir, 10% | $2.00M | — |
| DEBBANE RAYMOND | Dir | $723.0K | — |
| Martens Rachel Yap | SVP, Partnerships, Corp Strat | — | — |
| Gopinathan Suma | SVP, Discovery | — | — |
| Artal Participations S.a r.l. | Dir, 10% | — | — |
| Cheung Ivan | Dir | — | — |
| Exton Michael | CEO, Dir | — | — |
| Sullivan Diane E. | Dir | — | — |
| McDermott Wendy | SVP, Human Resources | — | — |
| Granowitz Craig B | SVP, Chief Medical Off | — | — |
Transactions 138
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-01 | 2023-02-28 | LXRX | McDermott Wendy | VP, Human Resources | F - Tax | $2.17 | -6,465 | 12.5K | -34% | -$14.0K |
| D | 2023-03-01 | 2023-02-28 | LXRX | MAIN ALAN J | EVP, Innov, Chem Sciences | F - Tax | $2.17 | -20.9K | 212.6K | -9% | -$45.5K |
| DM | 2023-03-01 | 2023-02-28 | LXRX | MAIN ALAN J | EVP, Innov, Chem Sciences | M - OptEx | — | +57.9K | 233.5K | +33% | — |
| D | 2023-03-01 | 2023-02-28 | LXRX | Seth Kiernan | VP, Chief Commercial Off | F - Tax | $2.17 | -11.8K | 53.1K | -18% | -$25.6K |
| DM | 2023-03-01 | 2023-02-28 | LXRX | Seth Kiernan | VP, Chief Commercial Off | M - OptEx | — | +43.1K | 36.7K | New | — |
| DM | 2023-03-01 | 2023-02-28 | LXRX | Alexander Kristen | VP, Fin, Accounting | M - OptEx | — | +18.7K | 35.7K | +110% | — |
| D | 2023-03-01 | 2023-02-28 | LXRX | Alexander Kristen | VP, Fin, Accounting | F - Tax | $2.17 | -5,330 | 30.4K | -15% | -$11.6K |
| D | 2023-03-01 | 2023-02-28 | LXRX | Granowitz Craig B | SVP, Chief Medical Off | F - Tax | $2.17 | -12.7K | 15.2K | -46% | -$27.6K |
| D | 2023-03-01 | 2023-02-28 | LXRX | Granowitz Craig B | SVP, Chief Medical Off | M - OptEx | — | +27.9K | 27.9K | New | — |
| DM | 2023-03-01 | 2023-02-28 | LXRX | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | M - OptEx | — | +52.9K | 138.7K | +62% | — |
| D | 2023-03-01 | 2023-02-28 | LXRX | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | F - Tax | $2.17 | -19.1K | 119.6K | -14% | -$41.5K |
| I | 2022-08-09 | 2022-08-05 | LXRX | DEBBANE RAYMOND | Dir, 10% | P - Purchase | $2.50 | +147.4K | 5.45M | +3% | +$368.5K |
| I | 2022-08-09 | 2022-08-05 | LXRX | Artal International S.C.A. | Dir, 10% | P - Purchase | $2.50 | +2.43M | 50.86M | +5% | +$6.07M |
| I | 2022-08-01 | 2022-08-01 | LXRX | DEBBANE RAYMOND | Dir, 10% | P - Purchase | $2.50 | +982.6K | 5.30M | +23% | +$2.46M |
| I | 2022-08-01 | 2022-08-01 | LXRX | DEBBANE RAYMOND | Dir | P - Purchase | $2.50 | +982.6K | 5.30M | +23% | +$2.46M |
| I | 2022-08-01 | 2022-08-01 | LXRX | Artal International S.C.A. | Dir, 10% | P - Purchase | $2.50 | +16.17M | 48.43M | +50% | +$40.43M |
| D | 2022-05-02 | 2022-04-30 | LXRX | BARKER SAM L | Dir | M - OptEx | $0.00 | +4,024 | 70.3K | +6% | $0 |
| D | 2022-05-02 | 2022-04-30 | LXRX | DEBBANE RAYMOND | Dir | M - OptEx | $0.00 | +4,024 | 331.5K | +1% | $0 |
| D | 2022-05-02 | 2022-04-30 | LXRX | Palantoni Frank | Dir | M - OptEx | $0.00 | +4,024 | 31.0K | +15% | $0 |
| D | 2022-05-02 | 2022-04-30 | LXRX | LEFKOWITZ ROBERT J MD | Dir | M - OptEx | $0.00 | +4,024 | 31.0K | +15% | $0 |
| D | 2022-05-02 | 2022-04-30 | LXRX | NIES ALAN S | Dir | M - OptEx | $0.00 | +4,024 | 31.7K | +15% | $0 |
| D | 2022-05-02 | 2022-04-30 | LXRX | SOBECKI CHRISTOPHER J | Dir | M - OptEx | $0.00 | +4,024 | 149.7K | +3% | $0 |
| D | 2022-05-02 | 2022-04-30 | LXRX | Swain Judith L | Dir | M - OptEx | $0.00 | +4,024 | 31.0K | +15% | $0 |
| D | 2022-05-02 | 2022-04-30 | LXRX | Amouyal Philippe | Dir | M - OptEx | $0.00 | +4,024 | 31.0K | +15% | $0 |
| DM | 2022-02-28 | 2022-02-28 | LXRX | Alexander Kristen | VP, Fin, Accounting | M - OptEx | — | +11.3K | 20.3K | +126% | — |
| D | 2022-02-28 | 2022-02-28 | LXRX | Alexander Kristen | VP, Fin, Accounting | F - Tax | $2.85 | -3,337 | 17.0K | -16% | -$9,510 |
| DM | 2022-02-28 | 2022-02-28 | LXRX | Seth Kiernan | VP, Chief Commercial Off | M - OptEx | — | +30.1K | 24.8K | New | — |
| D | 2022-02-28 | 2022-02-28 | LXRX | Seth Kiernan | VP, Chief Commercial Off | F - Tax | $2.85 | -8,261 | 21.9K | -27% | -$23.5K |
| DM | 2022-02-28 | 2022-02-28 | LXRX | COATS LONNEL | CEO, Dir | M - OptEx | — | +197.3K | 516.1K | +62% | — |
| D | 2022-02-28 | 2022-02-28 | LXRX | COATS LONNEL | CEO, Dir | F - Tax | $2.85 | -48.1K | 586.0K | -8% | -$137.0K |
| D | 2022-02-28 | 2022-02-28 | LXRX | Crum Brian T | SVP, GC, Secr | F - Tax | $2.85 | -15.1K | 99.5K | -13% | -$42.9K |
| DM | 2022-02-28 | 2022-02-28 | LXRX | Crum Brian T | SVP, GC, Secr | M - OptEx | — | +40.9K | 114.5K | +56% | — |
| DM | 2022-02-28 | 2022-02-28 | LXRX | WADE JEFFREY L | Pres, CFO | M - OptEx | — | +66.9K | 219.5K | +44% | — |
| D | 2022-02-28 | 2022-02-28 | LXRX | WADE JEFFREY L | Pres, CFO | F - Tax | $2.85 | -25.8K | 193.7K | -12% | -$73.5K |
| DM | 2022-02-28 | 2022-02-28 | LXRX | MAIN ALAN J | EVP, Innov, Chem Sciences | M - OptEx | — | +54.6K | 163.1K | +50% | — |
| D | 2022-02-28 | 2022-02-28 | LXRX | MAIN ALAN J | EVP, Innov, Chem Sciences | F - Tax | $2.85 | -19.8K | 175.6K | -10% | -$56.3K |
| DM | 2022-02-28 | 2022-02-28 | LXRX | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | M - OptEx | — | +36.6K | 99.1K | +59% | — |
| D | 2022-02-28 | 2022-02-28 | LXRX | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | F - Tax | $2.85 | -13.2K | 85.9K | -13% | -$37.7K |
Purchase Sale Sale after option exercise All abbreviations